Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report
Megumu Osaki, Ryo Tachikawa, Junichiro Ohira, Shigeo Hara, Keisuke Tomii
Topics & Concepts
NivolumabMedicineDermatomyositisLung cancerCancerMuscle weaknessInternal medicineAdverse effectGastroenterologyImmunotherapyImmunologyInflammatory Myopathies and DermatomyositisCancer Immunotherapy and BiomarkersCancer Diagnosis and Treatment